ClinicalTrials.gg
Status unknownNCT01328236BortezomibUpdated Sep 22, 2011

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

A Phase 2 interventional study of Bortezomib and Liposome doxorubicin in Plasma Cell Leukemia and Multiple Myeloma, sponsored by Clinical Service, China. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-22.

Sponsored by Clinical Service, China · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2011), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Leukemia, Plasma Cell with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Leukemia, Plasma Cell · China.

Planned enrollment
11th of 19
20 · median 24
Started
2010
the only one that year
Phase 2
7 of 20
5 open now
Registered
1st of 20
by date
Lead sponsor
1 of 20
Clinical Service, China

Among the 20 studies in Leukemia, Plasma Cell with a site in China, this one is the 11th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2010, is one of 7 in phase 2, and was the 1st registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

17 of the 20 studies in Leukemia, Plasma Cell with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Plasma Cell with a site in China, or all of them as a file.
02

Study summary

Bortezomib/Liposomal doxorubicin (V-DD) is preferred to bortezomib single agent in salvage therapy for Multiple Myeloma (MM).

The present study is designed to assessment the efficacy and safety study of Bortezomib in combination with Liposomal Doxorubicin and Dexamethasone in treatment of Plasma Cell Leukemia (PCL).

Primary study endpoint is the overall response rate (sCR+CR+VGPR+PR). Secondary endpoints is the rate of complete response (sCR+CR), partial remission rate (VGPR + PR), duration of response (DOR), overall survival (OS).

Read the detailed description

Patient with Plasma Cell Leukemia(PCL ) and multiple myeloma (MM); KPS ≥ 60scores

03

Conditions studied

  • Plasma Cell Leukemia
  • Multiple Myeloma

Keywords

  • Bortezomib
  • PCL
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients confirmed PCL who previously untreated or never received treatment with Bortezomib
  • ≥ 60
  • Adequate liver and renal function within 2 weeks of Screening:
  • ≤ 1.5 × the (ULN)
  • (ALT) ≤ 2.5 × the upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) ≤ 2.5 × the upper limit of normal (ULN)
  • Cardiac function > Ⅲ grade and > 45%
  • Signed prior to initiation of any study-related procedures that are not considered standard of care

Exclusion criteria

Exclusion Criteria:

  • has taken Bortezomib
  • ≤ 60 scores
  • mental illness
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    V-DD single arm

    INDUCTION THERAPY: V-DD induction therapy for 6 cycles,28 Days per Cycle. Bortezomib - 1.3 mg/m2 IV, Days 1, 4, 8 , 11 of every treatment; Liposomal Doxorubicin - 30 mg/m2 IV, Day 4 of every treatment; Dexamethasone - 40 mg/d IV, Days 1 - 4 of every treatment. Maintenance treatment for 4 cycles,28 Days per Cycle. Thalidomide - 100mg Qn ; Bortezomib - 1.3 mg/m2 IV ,Days 1, 4, 8 and 11 of every treatment; Dexamethasone - 40 mg/d IV ,Days 1 - 4; Interferon - 300 u Qod,(Specially for IgA type). Interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.

    Drug: Bortezomib · Drug: Liposome doxorubicin · Drug: Dexamethasone

Interventions

  • INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1, 4, 8, 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops. MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1, 4, 8, 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.

    Also known as: Velcade

  • INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.

    Also known as: Caelyx

  • INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops. MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.

    Also known as: Acidocont, Deronil, Dexacortal, dexametona, Flumeprednisolon

06

What researchers measure

Primary outcomes

  1. overall response rate

    The overall response rate of V-DD in patients with PCL assessed by International Myeloma Working Group(IMWG) criteria

    Time frame: Day 1 of every treatment cycle

Secondary outcomes

  1. the rate of response

    The complete response rate of V-DD in patients with PCL assessed by International Myeloma Working Group(IMWG) criteria.

    Time frame: Day 1 of every treatment cycle

  2. partial remission rate

    The complete response rate of V-DD in patients with PCL assessed by International Myeloma Working Group(IMWG) criteria.

    Time frame: Day 1 of every treatment cycle

  3. duration of response

    Time frame: up to 6 months

  4. overall survival

    Time frame: up to two and a half year

  5. Adverse Events

    Occurrence of adverse events throughout the study using CTCAE ctriteria version 4.0.

    Time frame: up to two and a half years

  6. FACT/GOC-Ntx

    Time frame: Day 1 of every treatment cycle

07

Study locations

1 of 1 sites recruiting
  • Beijing Clinical Service Center
    Beijing, Beijing, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Sep 2013 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2011
First posted
Apr 4, 2011
Start
Sep 2010
Primary completionEst.
Sep 2013
CompletionEst.
Sep 2015
Last update
Sep 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01328236
Lead sponsor
Clinical Service, China
Collaborators
Harbin Hematology and Oncology Institute, Shanghai Changzheng Hospital, Chinese PLA General Hospital, 307 Hospital of PLA, Wuhan Union Hospital, China, Beijing Chao Yang Hospital, Henan Provincial People's Hospital, Peking University Third Hospital
Responsible party
wangzhao (Beijing Friendship Hospital, Clinical Service, China) — Principal investigator
First posted
Apr 4, 2011
Start date
Sep 2010
Primary completion
Sep 2013 (estimated)
Completion
Sep 2015 (estimated)
Last update
Sep 22, 2011

Study contacts

zhao wang, Master
principal investigator · Beijing Friendship Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Dexamethasone

Start the discussion